Veteran executive joins DarioHealth (NASDAQ: DRIO) board to drive scaling

Rhea-AI Filing Summary

DarioHealth Corp. has appointed veteran healthcare executive John R. Palumbo to its Board of Directors, effective April 10, 2026. Palumbo, age 75, has more than four decades of operating experience across early-stage ventures and large healthcare companies, including leadership roles at AmerisourceBergen, Allscripts and Shared Medical Systems.

He has guided organizations through transformative growth, including supporting two IPOs and major operational and commercial transformations, and currently serves on several healthcare and digital health boards. Dario expects his deep relationships with health systems, payers and senior healthcare executives to support its next phase of partner-led commercial scaling and expansion across payer, provider and health services markets.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Director age: 75 years Healthcare experience: More than 40 years Companies through IPOs: Two companies

3 metrics

Director age 75 years Age of John R. Palumbo at appointment

Healthcare experience More than 40 years Healthcare operating experience across ventures and Fortune 100 companies

Companies through IPOs Two companies Organizations Palumbo supported through IPOs

Key Terms

digital therapeutics, emerging growth company, forward-looking statements, Nasdaq Capital Market, +1 more

5 terms

digital therapeutics financial

"a multi-chronic condition digital therapeutics platform"

Digital therapeutics are clinically proven software programs or apps designed to prevent, manage or treat medical conditions, often used alongside or instead of drugs and devices. They matter to investors because they can scale like software, require regulatory approval and payment from insurers or health systems, and thus offer potential recurring revenue, lower delivery costs and new market opportunities in healthcare — like a virtual prescription that replaces or enhances traditional treatment.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

forward-looking statements regulatory

"contain or may contain forward-looking statements within the meaning"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Nasdaq Capital Market financial

"Common Stock, par value $0.0001 per share ... The Nasdaq Capital Market LLC"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Regulation S-K regulatory

"requiring disclosure under Item 404(a) of Regulation S-K"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

Understanding 8-K Material Events →

false 0001533998 0001533998 2026-04-10 2026-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 10, 2026

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-37704		45-2973162
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

322 W 57th St., #33B
New York, New York 10019

(Address of Principal Executive Offices)

972- 4-770-6377

(Issuer’s telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which  registered
Common Stock, par value $0.0001 per share		DRIO		The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of John R. Palumbo to Board of Directors

On April 10, 2026, on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as a member of the Board, effective immediately.

Mr. Palumbo, 75, brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises, guiding organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations. Since August 2023, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of PM Pediatrics Management Group, LLC, a specialized urgent care provider that offers comprehensive, evidence-based medical and mental health services for children and young adults from birth through age 26. Since September 2025, Mr. Palumbo has served on the Board of Directors, and the audit and compensation committees, of Lucid Diagnotics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Since May 2025, Mr. Palumbo has served on the Board of Directors of ivWatch, LLC, a medical device company that develops and manufactures the world's only FDA-cleared and CE-marked biosensor technology designed to continuously monitor peripheral IV sites for early detection of infiltration and extravasation events. Since September 2025, Mr. Palumbo has served on the Board of Directors, and the compensation committee, of QLess, a cloud-based software company that provides a mobile queuing and appointment scheduling platform designed to eliminate physical waiting lines by allowing customers to join virtual queues via their phones. Since June 2023, Mr. Palumbo has chaired the advisory board of Brado Ai, an AI-driven conversational engagement platform serving health systems.

Mr. Palumbo received a B.S. in Business Management from Widener University. Mr. Palumbo brings to the Board valuable experience from his career in healthcare serving in senior leadership, private equity, management, advisory and industry operating roles.

As remuneration for his service as a director, Mr. Palumbo will receive the same fees as the Company’s other non-executive directors. There is no arrangement or understanding between Mr. Palumbo and any other person pursuant to which he was elected as a director, and except as otherwise described herein, there are no transactions in which Mr. Palumbo has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item 8.01 Other Events.

On April 13, 2026, the Company issued a press release announcing the appointment of Mr. Palumbo to its Board. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.  

(d) Exhibits.

Exhibit Number		Description
99.1		Press release dated April 13, 2026.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 13, 2026	DARIOHEALTH CORP.
	By:	/s/ Chen Franco-Yehuda
	Name:	Chen Franco-Yehuda
	Title:	Chief Financial Officer, Treasurer and Secretary

Exhibit 99.1

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of
Directors to Support Accelerated Commercial Scaling

Mr. Palumbo’s deep relationships across health systems, payers and healthcare’s senior executive community expected to accelerate Dario’s commercial partnerships and position the Company to realize its full strategic value

NEW YORK, April 13, 2026 – DarioHealth Corp. (NASDAQ: DRIO) (the “Company” or “Dario”), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors. The addition reflects Dario’s continued alignment of board composition with its next phase of commercial scaling.

Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises. His substantial background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and leadership positions at Shared Medical Systems Corporation (Siemens Aktiengesellschaft).

“John’s appointment is highly intentional and strategically valuable,” stated Dario's Chief Executive Officer, Erez Raphael. “As we transition from demonstrating the strength of our distribution model to scaling it efficiently through channel partnerships, we are adding leaders to our board who have done exactly that. John brings a rare combination of strategic insight, operational discipline and deep industry relationships that will directly support our growth trajectory. He has been at the center of some of healthcare’s most consequential strategic transactions and organizational transformations, and his relationships with senior decision-makers across the payer, provider and health services landscape will be invaluable as we continue to build and scale. We are increasingly confident that the market will come to fully reflect the value we have built – and we are not standing still while that recognition develops.”

Mr. Palumbo has guided organizations through transformative growth, including supporting two companies through IPOs and leading large-scale operational and commercial transformations. His experience is particularly relevant to Dario’s evolution toward a more capital-efficient, partner-led go-to-market strategy. He brings deep familiarity with the care delivery ecosystem, including the health systems, payers and provider services organizations that are shaping its consolidation – adding a dimension of strategic reach that directly complements Dario’s next phase.

In addition to his operating capabilities, Mr. Palumbo is actively engaged in the digital health ecosystem. He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems.

“Dario is at a compelling inflection point,” said Mr. Palumbo. “The Company has built a differentiated, integrated solution with strong engagement which is delivering proven economic and clinical outcomes. The opportunity now is to scale that value through the right commercial channels and ensure the Company captures the full strategic opportunity its platform represents. I look forward to working closely with management to help accelerate both our commercial momentum and the value creation this platform deserves.”

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that Mr. Palumbo’s experience will directly support its growth trajectory, its belief that adding Mr. Palumbo as a member of the Board will be instrumental in guiding Dario’s continued expansion within the payer, provider and health services markets and its expectation that Mr. Palumbo’s appointment will accelerate Dario’s commercial partnerships and position the Company to realize its full strategic value. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing

irteam@dariohealth.com

FAQ

What did DarioHealth (DRIO) announce in this Form 8-K?

DarioHealth announced the appointment of John R. Palumbo to its Board of Directors, effective April 10, 2026. The company highlighted his extensive healthcare operating experience and board roles as support for Dario’s next phase of commercial scaling and strategic expansion in payer, provider and health services markets.

Who is John R. Palumbo, newly appointed to DarioHealth’s board?

John R. Palumbo is a 75-year-old healthcare executive with more than 40 years of operating experience. He has held senior roles at AmerisourceBergen, Allscripts and Shared Medical Systems, helped guide two companies through IPOs, and led large-scale operational and commercial transformations across the healthcare sector.

Why is DarioHealth adding John R. Palumbo to its Board of Directors?

DarioHealth states that John R. Palumbo’s appointment is intended to support its next phase of commercial scaling. His strategic insight, operational discipline and deep relationships with health systems, payers and senior healthcare decision-makers are expected to help accelerate commercial partnerships and realize the company’s full strategic value.

What other board roles does John R. Palumbo hold alongside DarioHealth?

John R. Palumbo serves on the boards and key committees of PM Pediatrics Management Group, Lucid Diagnostics Inc., ivWatch, LLC and QLess, Inc. He also chairs the advisory board of Brado Ai, an AI-driven engagement platform serving health systems, reflecting broad involvement across healthcare and digital health sectors.

How will John R. Palumbo be compensated for serving on DarioHealth’s board?

DarioHealth states that John R. Palumbo will receive the same fees as the company’s other non-executive directors. The filing notes there is no special arrangement or understanding under which he was elected, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

What is DarioHealth’s business focus as described in the filing?

DarioHealth is described as a digital health company with a multi-condition digital therapeutics platform for chronic conditions. Its solutions target diabetes, hypertension, weight management, musculoskeletal pain and behavioral health, delivering personalized, data-driven interventions and one-on-one coaching to health plans, self-insured employers, care providers and consumers globally.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 13.2 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB